Next-gen obesity drug race tightens as pivotal readouts loom
TL;DR Summary
Pharma is racing to commercialize next-generation obesity drugs as pivotal readouts approach from Lilly, Viking Therapeutics, and Pfizer; Lilly’s retatrutide shows potentially stronger weight loss and knee-pain relief in Triumph-4, Viking is testing maintenance dosing for VK2735, and Pfizer’s PF’3944 posted encouraging phase 2b results for monthly maintenance injections, signaling a crowded path to a multi-billion GLP-1 market by 2030.
- Race intensifies to lead next wave of obesity drugs as trial results loom Pharma Voice
- Framework for the pharmacological treatment of obesity and its complications from the European Association for the Study of Obesity (EASO): 2026 update Nature
- Beyond Mounjaro: Korean drugmakers chase monthly obesity shot The Korea Herald
- ECO 2026: targeting organs, not just weight, defines next wave of obesity therapy Clinical Trials Arena
- Obesity Treatment Development: Challenges and Future Focus Technology Networks
Reading Insights
Total Reads
0
Unique Readers
8
Time Saved
15 min
vs 16 min read
Condensed
98%
3,081 → 60 words
Want the full story? Read the original article
Read on Pharma Voice